7Baggers
 IMAB: Leerink Partners Initiates Coverage with "Outperform" Rati  GuruFocus Fri, 03 Oct 2025 11:47:07 GMT
 I-Mab initiated with an Outperform at Leerink  TipRanks Fri, 03 Oct 2025 10:38:58 GMT
 Published on: 2025-09-29 23:28:31  newser.com Tue, 30 Sep 2025 04:28:31 GMT
 I-Mab to Vote on Name Change to NovaBridge Biosciences  TipRanks Thu, 25 Sep 2025 10:16:45 GMT
 i-mab (nasdaq:imab) rating lowered to "hold" at wall street zen  MarketBeat Tue, 23 Sep 2025 07:00:00 GMT
 i-mab (nasdaq:imab) downgraded by wall street zen to "hold"  MarketBeat Mon, 22 Sep 2025 22:48:46 GMT
 i-mab (nasdaq:imab) lowered to "hold" rating by wall street zen  MarketBeat Mon, 22 Sep 2025 09:28:56 GMT
 i-mab (nasdaq:imab) stock rating lowered by wall street zen  MarketBeat Sat, 20 Sep 2025 05:52:55 GMT
 i-mab (nasdaq:imab) rating lowered to "hold" at wall street zen  MarketBeat Sat, 20 Sep 2025 05:52:55 GMT
 i-mab biopharma: a deep dive (nasdaq:imab)  Seeking Alpha Tue, 16 Sep 2025 07:00:00 GMT
 btig research initiates coverage on i-mab (nasdaq:imab)  MarketBeat Sun, 14 Sep 2025 07:00:00 GMT
 btig research initiates coverage on i-mab (nasdaq:imab)  MarketBeat Sat, 13 Sep 2025 07:00:00 GMT
 i-mab (nasdaq:imab) now covered by btig research  MarketBeat Thu, 11 Sep 2025 12:25:06 GMT
 i-mab (nasdaq:imab) coverage initiated at btig research  MarketBeat Thu, 11 Sep 2025 12:25:06 GMT
 btig says buy i-mab amid ‘misperceived’ china risk  MSN Thu, 11 Sep 2025 02:07:10 GMT
 needham & company llc reaffirms buy rating for i-mab (nasdaq:imab)  MarketBeat Wed, 10 Sep 2025 16:11:29 GMT
 i-mab initiated with a buy at btig  MSN Wed, 10 Sep 2025 10:49:56 GMT
 btig says buy i-mab amid ‘misperceived’ china risk  TipRanks Wed, 10 Sep 2025 07:00:00 GMT
 btig initiates i-mab at buy with $7 price target  MarketScreener Tue, 09 Sep 2025 07:00:00 GMT
 i-mab initiated with a buy at btig  TipRanks Tue, 09 Sep 2025 07:00:00 GMT
 i-mab to accelerate investment in givastomig  MSN Mon, 08 Sep 2025 18:07:44 GMT
 i-mab expands investment in givastomig; wei fu named executive chair  MarketScreener Mon, 08 Sep 2025 13:38:09 GMT
 i-mab to initiate phase 2 study for gastric cancer drug in q1 2026  Investing.com UK Mon, 08 Sep 2025 12:42:00 GMT
 I-Mab to accelerate investment in givastomig (IMAB:NASDAQ)  Seeking Alpha Mon, 08 Sep 2025 07:00:00 GMT
 new analyst forecast: $imab given $6.0 price target | imab stock news  Quiver Quantitative Mon, 08 Sep 2025 07:00:00 GMT
 i-mab announces board and leadership appointments  MarketScreener Mon, 08 Sep 2025 07:00:00 GMT
 i-mab announces accelerated investment in givastomig program  TipRanks Mon, 08 Sep 2025 07:00:00 GMT
 i-mab sees cash runway through 4q28  MSN Sat, 06 Sep 2025 00:42:57 GMT
 i-mab sees cash runway through 4q28  MSN Fri, 05 Sep 2025 12:54:18 GMT
 published on: 2025-08-31 16:31:11  Newser Sun, 31 Aug 2025 21:31:11 GMT
 i-mab insiders land bargain with gains of us$5.0m  Yahoo Finance Sun, 31 Aug 2025 13:55:54 GMT
 published on: 2025-08-31 07:31:35  Newser Sun, 31 Aug 2025 12:31:35 GMT
 published on: 2025-08-31 03:08:56  Newser Sun, 31 Aug 2025 08:08:56 GMT
 published on: 2025-08-30 16:24:23  Newser Sat, 30 Aug 2025 21:24:23 GMT
 published on: 2025-08-29 13:08:03  Newser Fri, 29 Aug 2025 18:08:03 GMT
 equities analysts offer predictions for i-mab q3 earnings  MarketBeat Fri, 29 Aug 2025 07:00:00 GMT
 i-mab stock price target raised to $8 from $6 at brookline capital  Investing.com Australia Fri, 29 Aug 2025 07:00:00 GMT
 published on: 2025-08-28 04:29:29  Newser Thu, 28 Aug 2025 09:29:29 GMT
 published on: 2025-08-28 04:05:40  Newser Thu, 28 Aug 2025 09:05:40 GMT
 I-Mab stock price target raised to $8 from $6 at Brookline Capital  Investing.com Thu, 28 Aug 2025 07:00:00 GMT
 i-mab (nasdaq:imab) upgraded by wall street zen to "buy" rating  MarketBeat Thu, 28 Aug 2025 07:00:00 GMT
 published on: 2025-08-27 07:38:32  Newser Wed, 27 Aug 2025 12:38:32 GMT

I-Mab
(NASDAQ:IMAB) 

IMAB stock logo

I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody th...

Founded: 2014
Full Time Employees: 229
CEO: Huaqiong Shen  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends